Posted On: 07/16/2014 8:15:00 PM
Post# of 5

REPCF Financials 07/16/2014 19:15:04
RepliCel Life Sciences Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 3,878 - - -
Cost of Revenue - - - -
Gross Profit 3,878 - - -
Operating Expenses
Research and Development 1,470 1,070 1,001 554
Sales, General and Admin. 2,047 3,424 2,665 1,880
Non-Recurring Items - - - 118
Other - - - 7
Operating Income 361 (4,493) (3,666) (2,559)
Income From Continuing Operations
Add'l Income/Expense Items - 1,116 20 -
Earnings Before Interest and Tax 361 (3,378) (3,647) (2,559)
Interest Expense - - - -
Earnings Before Tax 361 (3,378) (3,647) (2,559)
Income Tax 388 - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (27) (3,378) (3,647) (2,559)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (27) (3,378) (3,647) (2,559)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (27) (3,378) (3,647) (2,559)
RepliCel Life Sciences Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 3,878 - - -
Cost of Revenue - - - -
Gross Profit 3,878 - - -
Operating Expenses
Research and Development 1,470 1,070 1,001 554
Sales, General and Admin. 2,047 3,424 2,665 1,880
Non-Recurring Items - - - 118
Other - - - 7
Operating Income 361 (4,493) (3,666) (2,559)
Income From Continuing Operations
Add'l Income/Expense Items - 1,116 20 -
Earnings Before Interest and Tax 361 (3,378) (3,647) (2,559)
Interest Expense - - - -
Earnings Before Tax 361 (3,378) (3,647) (2,559)
Income Tax 388 - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (27) (3,378) (3,647) (2,559)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (27) (3,378) (3,647) (2,559)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (27) (3,378) (3,647) (2,559)

